Anti-Synthetase Syndrome

Research Updates (10)Clinical Trials (11)

Browse recruiting and upcoming clinical trials for anti-synthetase syndrome.

Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026

About this listHide

ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.

11 trials

Showing 11 trials

Recruiting
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
NCT07715136
Who can join AIAdults aged 18–60 with refractory idiopathic inflammatory myopathy (IIM), including dermatomyositis, immune‑mediated necrotizing myopathy, polymyositis, or antisynthetase syndrome.
What is being studied AITests safety and tolerability of a single ICG318 CAR‑T infusion after lymphodepletion.
Study typeTreatment (drug) · Phase 1
CountriesChina
View trial
Recruiting
A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome
NCT07406932
Who can join AIAdults 18–75 with antisynthetase syndrome and interstitial lung disease (ILD) who need initial immunosuppressive therapy.
What is being studied AICompares JAK inhibitors with calcineurin inhibitors as initial drug treatment for ASS-associated ILD.
Study typeTreatment (drug)
CountriesChina
View trial
Recruiting
Descartes-08 in Autoantibody Myositis
NCT07391605
Who can join AIAdults (18+) with dermatomyositis or antisynthetase syndrome who have muscle and/or skin involvement and meet study criteria.
What is being studied AITests Descartes-08 (autologous BCMA-directed CAR T cells) versus placebo for autoantibody myositis.
Study typeTreatment (drug) · Phase 2
CountriesUnited States
View trial
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
NCT07085104
Who can join AIAdults with systemic lupus erythematosus (with or without nephritis), idiopathic inflammatory myopathy, or systemic sclerosis.
What is being studied AITests safety, tolerability, and initial biological activity of ALLO-329 allogeneic CAR T therapy.
Study typeTreatment (drug) · Phase 1
CountriesCanada, United States
View trial
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252
Who can join AIPeople age 6–75 with active idiopathic inflammatory myopathy, including dermatomyositis, anti‑synthetase syndrome, immune‑mediated necrotizing myopathy, or juvenile myositis.
What is being studied AITests safety and efficacy of CABA-201 (autologous CD19 CAR-T) in active myositis.
Study typeTreatment (drug)
CountriesUnited Kingdom, United States
View trial
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Trial of Fufei Huazhuo Tongluo Formula Combined With Standardized Medicine in Patients With Anti-Synthetase Syndrome-Associated Interstitial Lung Disease
NCT07836790
Who can join AIPeople with anti-synthetase syndrome-associated interstitial lung disease (ASS-ILD).
What is being studied AICompares FuFei Huazhuo TongLuo Granule plus standard medicine with placebo plus standard medicine.
Study typeTreatment (drug)
CountriesChina
View trial
Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441
Who can join AIAdults (≥18) with active idiopathic inflammatory myopathy (dermatomyositis, polymyositis, IMNM, antisynthetase syndrome) who completed ARGX-113-2007.
What is being studied AITests long-term safety, tolerability, and clinical effects of subcutaneous efgartigimod in adults with myositis.
Study typeTreatment (drug) · Phase 3
CountriesArgentina, Austria, Belgium +26
View trial
Recruiting
Environmental Risk Factors for the Anti-synthetase Syndrome
NCT01276470
Who can join AIPeople with myositis (including dermatomyositis, polymyositis, and juvenile forms) and healthy volunteers.
What is being studied AICompares past environmental exposures; collects questionnaires, blood, urine, and house dust samples.
Study typeObservational
CountriesUnited States
View trial